Summary
The antitumor activity of 5-aza-2′-deoxycytidine (5-aza-dCyd), a nucleoside analog, was established in human head and neck cancer xenografts, transplanted in nude mice. A significant response was noted in 3 of 5 lines, when the drug was injected intraperitoneally at a maximum tolerated dose of 2 mg/kg every four days for three doses. In two most sensitive lines 1 out of 6 tumors regressed completely. The antitumor activity of the drug may depend on the schedule used, as illustrated by the fact that just one of these two lines appeared to be sensitive when treated with low daily doses (0.25 mg/kg). One of the two sensitive lines also responded to the treatment with low daily doses (0.25 mg/kg). In two lines, 5-aza-dCyd showed equal or better antitumor activity when compared to the conventional drugs known to produce remissions in patients with head and neck cancer (cisplatin, methotrexate, bleomycin, 5-fluorouracil and cyclophosphamide). 5-Aza-dCyd is a drug with potential value in the chemotherapeutic treatment of patients with head and neck cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rowland KM, Taylor SG, Spiers ASD, DeConti RC, O'Donnell MR, Showel J, Stott PB, Milner LM, Marsh JC: Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: An Eastern Cooperative Oncology Group pilot study. Cancer Treat Rep 70:461–464, 1986
Tannock IF, Browman G: Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer. J Clin Oncol 4:1121–1126, 1986
Winograd B, Boven E, Lobbezoo MW, Pinedo HM: Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development (review). In Vivo 1:1–14, 1987
Van Groeningen CJ, Leyva A, O'Brien AMP, Gall HE, Pinedo HM: Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 46:4831–4836, 1986
Momparler RL, Goodman J: In vitro cytotoxic and biochemical effects of 5-aza-2′-deoxycytidine. Cancer Res 37:1636–1639, 1977
Covey JM, Zaharko DS: Comparison of the in vitro cytotoxicity (L1210) of 5-aza-2′-deoxycytidine with its therapeutic and toxic effects in mice. Eur J Cancer Clin Oncol 21: 109–117, 1985
Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin K, Momparler LF: Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leukemia Res 5:453–462, 1981
Covey JM, D'Incalci M, Tilchen EJ, Zaharko DS, Kohn KW: Differences in DNA damage produced by incorporation of 5-aza-2′-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res 46:5511–5517, 1986
Wilson VL, Jones PA, Momparler RL: Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res 43:3493–3496, 1983
Creusot F, Acs G, Christman JK: Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 257:2041–2048, 1982
Leyva A, Schwartsmann G, Boeije LCM, Pinedo HM, de Waal F: Growth inhibitory effects of 5-aza-2′-deoxycytidine in HL-60 promyelocytic leukemia cells resistant to differentiation induction. Biochem Biophys Res Comm 141: 629–635, 1986
Braakhuis BJM, Sneeuwloper G, Snow GB: The potential of the nude mouse xenograft model for the study of head and neck cancer. Arch Otorhinolaryngol 239:69–79, 1984
Roa A, Carey TE, Passamani PP, Greenwood JH, Hsu S, Ridings O, Schwartz DR, Wolf GT, Hudson JL: DNA content of human squamous cell carcinoma cell lines. Arch Otolaryngol 111:565–575, 1985
Momparler RL: Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine. Pharmac Ther 30:287–299, 1985
Momparler RL, Samson J, Momparler LF, Rivard GE: Cell cycle effects and cellular pharmacology of 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 13:191–194, 1984
D'Incalci M, Covey JM, Zaharko DS, Kohn KW: DNA alkali-labile sites induced by incorporation of 5-aza-2′-deoxycytidine into DNA of mouse leukemia L1210 cells. Cancer Res 45:3197–3202, 1985
Dale BA, Gown AM, Fleckman P, Kimball JR, Resing KA: Characterization of two monoclonal antibodies to human epidermal keratohyalin: reactivity with filaggrin and related proteins. J Invest Dermatol 88:306–313, 1987
Braakhuis BJM, Schoevers EJ, Heinerman ECM, Sneeuwloper G, Snow GB: Chemotherapy of human head and neck cancer xenografts with three clinically active drugs: cis-platinum, bleomycin and methotrexate. Br J Cancer 48:711–716, 1983
Fiebig HH, Widmer K-H, Fiedler L, Wittekind C, Löhr GW: Development and characterization of 51 human tumor models of large bowel, stomach and esophageal cancers. Dig Surg 1:225–235, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Braakhuis, B.J.M., van Dongen, G.A.M.S., van Walsum, M. et al. Preclinical antitumor activity of 5-aza-2′-deoxycytidine agains human head and neck cancer xenografts. Invest New Drugs 6, 299–304 (1988). https://doi.org/10.1007/BF00173648
Issue Date:
DOI: https://doi.org/10.1007/BF00173648